Join us for the 2024 Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium
February 25, 2024 at 2 P.M.
The symposium will be held in The DeJoy Family Club room, located in the Blue Devil Tower.
The symposium is free to attend and includes a virtual option for those that would like to participate via Zoom.
Following the Symposium, we will be cheering on the Duke Women's Basketball team at 5:30 P.M. at Cameron Indoor Stadium.
Click here to register for Virtual Symposium
We have run out of our supply of game tickets. Please visit goduke.com to purchase tickets.
Benefiting Endometrial Cancer research
We are here to raise awareness about endometrial cancer and support for research to help patients with this type of cancer live longer and healthier lives. Endometrial cancer, a cancer involving the inside lining of the uterus, is the leading gynecological cancer affecting women in the United States. Approximately 66,000 patients were diagnosed with endometrial cancer in 2023 and almost 13,030 died from the disease this year. That number is not going down. This cancer is more common in Black patients that white patients, and Black women are more likely to die from it. Patients who have endometrial cancer live wonderful, vibrant lives outside of their cancer diagnosis, and we want to honor them by finding new ways to treat endometrial cancer.
The answer is education, prevention, and research.
With the initial support of the Kay Yow "Cancers that Affect Women" grant in 2019, Angeles Alvarez Secord, MD, MHSc and Duke Cancer Institute created an Endometrial Cancer Consortium. The original nine-member consortium continues to grow and now includes 20 sites across the country. The consortium has expanded our research capabilities by harnessing information about endometrial cancer, the tumor makeup on a molecular level, what helps endometrial cancers to grow, and treatment outcomes. With this information we hope to identify the right targeted therapy to use for treatment based on the tumor makeup and provide individualized care for our patients. Our goal is to decrease the burden of endometrial cancer, improve survival outcomes, and accelerate research progress.
At the 2023 International Gynecologic Cancer Society Annual Meeting in Seoul, South Korea, Angeles Alvarez Secord, MD, MHSc, presented real-word data — from the DCI-based Endometrial Cancer Molecularly Targeted Therapy Consortium she leads — on pembrolizumab and lenvatinib prescribing patterns for endometrial cancer patients.